
Management Team
ExeVir can count on an experienced management team able to leverage international expertise to rapidly advance VHH72-Fc through clinical development to reach patients and build the viral control platform.

Torsten Mummenbrauer
Chief Executive Officer
Torsten Mummenbrauer
Torsten is CEO of ExeVir Bio. He brings nearly 25 years of experience in biotech and pharma to the role.
In prior roles, Torsten served as CEO of Velvio GmbH, Senior Vice President Business Development of Hookipa Pharma, Senior Director Business Development of Morphosys and Vice President Business Development of GSK, leading the transaction team of GSK vaccines. Torsten is reviewer of the German biotech seed fund program GoBio since almost 10 years and holds a PhD in Tumor Virology and Immunology from the University Hospital Hamburg.
Beyond his pharma and biotech engagement Torsten loves biking, skiing and windsurfing.

Fiona du Monceau
Chief Operating Officer
Fiona du Monceau
Fiona is COO of ExeVir Bio. She brings nearly 20 years of experience in life sciences to the role.
Previously, Fiona was Venture Partner at UCB Ventures. In prior roles, Fiona served as Evenity Commercial Lead and Head of EU, Bone at UCB. Prior to UCB, she led various teams at Eli Lilly, launching products across multiple therapeutics areas, managing business units and implementing changes through patent exclusivities and new models. Previously, Fiona also worked for McKinsey & Company covering healthcare clients in the US and Europe and worked in business development at GSK Biologicals. Fiona has an MBA from Harvard Business School and a MSc in Management from the Solvay Business School (ULB). She is a Fulbright and a Belgian American Education Foundation (BAEF) scholar. Fiona is a governor of the London Business School and a member of their audit and risk committee.
In her free time, she enjoys spending time with her husband and four children, skiing, hiking and being outdoors.

Xavier Saelens
Scientific Founder & Research Collaborator
Xavier Saelens
Professor Xavier Saelens, scientific founder of Exevir is a Group Leader at the VIB-UGent Center for Medical Biotechnology at VIB and a full Professor Molecular Virology at Ghent University.
His research is primarily focused on influenza and respiratory syncytial virus. The aim of this research is to develop new vaccines and antibody-based intervention strategies to prevent and treat disease caused by these and other important human respiratory viruses. A second line of research in the Saelens group aims to increase our knowledge on the molecular interactions between influenza and respiratory syncytial virus and their human host.

Nico Callewaert
Scientific Founder & Research Collaborator
Nico Callewaert
Professor Nico Callewaert, scientific founder of ExeVir, is Director at the VIB Center for Medical Biotechnology and Professor of Biochemistry and Biotechnology at Ghent University.
Based on strengths in glycobiology, microbial biotechnology, biological system’s engineering and bio-analytics, his research group is developing innovative molecular technology to enable novel approaches to the study, diagnosis and treatment of disease. Nico and his team have ample expertise in Protein production in mammalian cells, FEMTO Pulse Automated Pulsed-Field CE instrument, Sugar analysis – glycomics (DSA-FACE), Protein production in yeast, Recombinant DNA techniques for synthetic biology.